UNIVERSITY OF TECHNOLOGY SYDNEY

Their core work

UTS is a major Australian research university contributing to European research primarily through MSCA-RISE staff exchange programmes. Their H2020 involvement spans biomedical materials, wireless body-centric communications, respiratory disease treatment, and applied mathematics (turbulence modelling). They bring a non-European perspective and expertise in health technology — particularly wearable sensors, body-area networks, and palliative care research — serving as a third-party knowledge partner rather than a project driver.

What they specialise in

How they've shifted over time

UTS's early H2020 involvement (2015–2017) centred on materials science and social information processing — broadly exploratory, with limited health focus beyond the LungCARD lung cancer project. From 2019 onward, their portfolio shifted decisively toward health-adjacent topics: palliative care for respiratory disease (BETTER-B), wireless body-area networks for patient monitoring (ROVER), and continued lung disease work. This suggests an institutional consolidation around health technology and patient-centred care research.

UTS is converging on the intersection of digital health technology and chronic respiratory disease, making them a strong future partner for remote patient monitoring and e-health projects.

How they like to work

UTS participates almost exclusively as a third-party partner (6 of 7 projects), never as coordinator, typically joining large European consortia through MSCA-RISE mobility schemes. With 89 unique partners across 36 countries, they maintain a broad but shallow network — many different collaborators rather than deep repeat partnerships. This profile indicates a university that offers specialist expertise on demand rather than driving project strategy.

UTS has collaborated with 89 unique partners across 36 countries, an exceptionally wide geographic spread reflecting their role in MSCA-RISE staff exchange programmes. Their network is truly global, connecting European consortia with Australian research capacity.

What sets them apart

As one of relatively few Australian universities active in H2020, UTS offers European consortia access to Asia-Pacific research networks, clinical cohorts, and regulatory environments that are otherwise hard to reach. Their dual strength in wireless health sensing hardware (ROVER) and respiratory clinical research (BETTER-B, LungCARD) positions them uniquely at the engineering-medicine interface. For consortium builders needing a credible non-European partner with health technology expertise, UTS is a proven and well-connected choice.

Highlights from their portfolio

• BETTER-B
  UTS's only project as a direct participant (not third party), and their most health-focused: a multi-country clinical trial for breathlessness treatment in palliative care.
• ROVER
  Directly bridges engineering and healthcare — reliable wireless body-centric communications with applications in patient monitoring, 5G, and human-centric localisation.
• LungCARD
  Blood-based diagnostic test for guiding non-small cell lung cancer therapy — connects UTS to the precision medicine and liquid biopsy space.